NASDAQ: BYSI · Life Sciences · 7 alerts · CIK 1677940
Share price
$0.5788Close, Nov 16
Market cap
$24M
Shares outstanding
41.41MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BeyondSpring Inc. filings on SEC EDGAR ↗
BeyondSpring Divestiture to Biolin Investment Limited
BeyondSpring Inc. completed the sale of its entire issued share capital in BeyondSpring Ltd. to Biolin Investment Limited, effectively divesting its interests in Dalian Wanchunbulin Pharmaceuticals and SEED Therapeutics. The transaction was for non-cash consideration, consisting of a strategic collaboration where the investor funds and completes the China portion of the DUBLIN-4 Phase 3 clinical trial. BeyondSpring retains rights to the clinical data generated from the trial and a potential equity clawback if enrollment targets are not met.
BeyondSpring Divestiture to Biolin Investment Limited
BeyondSpring entered into a definitive agreement to sell its majority equity interest in its Chinese subsidiary, Bulin, to Biolin Investment Limited. In exchange for the equity, the investor will fund and conduct the China portion of the global Phase 3 DUBLIN-4 trial for Plinabulin, which is expected to cover approximately 50% of the total trial enrollment.